Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hyatt Hotels Corporation (H) vs Eli Lilly And Co (LLY) Price & Performance

Hyatt Hotels CorporationTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Hyatt Hotels Corporation vs Eli Lilly And Co — how do they compare? Hyatt Hotels Corporation trades at $175.66 (market cap $16.27B), while Eli Lilly And Co trades at $1,216 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 66.4× Hyatt Hotels Corporation's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.

HLLY
Market Cap
$16.27B$1.08T
Sector
Consumer CyclicalHealth
52-Week High
$202.09$1.24K
52-Week Low
$135.42$639.43
Enterprise Value
$20.17B$1.13T
Dividend Yield
0.35%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hyatt Hotels Corporation

Hyatt Hotels Corp (H) trades at $170.08, down 4.29% on the day, reflecting a bearish technical trend with key support at $167. Fundamentally, the company shows revenue growth to $7.10B in 2025 but reported a net loss of $52M, with a high P/E ratio of 213.14 indicating premium valuation. Recent Q2 2026 earnings beat expectations with EPS of $1.12, driven by strong fee growth and RevPAR gains, as reported by Business Wire on July 30, 2026.

The outlook is mixed; analyst consensus is a 'Hold' with a $199.55 price target, suggesting 17% upside, but high debt and regional weaknesses pose risks. Investment opportunity hinges on sustained operational momentum offsetting valuation concerns, with key risks including project delays and macroeconomic pressures on travel demand.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hyatt Hotels Corporation

Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.

Read more on H

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY